Yukinori Sakao

Prof. Yukinori Sakao


Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
KIKentaro Inamura
Kentaro Inamura
KTKengo Takeuchi
Kengo Takeuchi
YTYuki Togashi
Yuki Togashi
SHSatoko Hatano
Satoko Hatano
HNHironori Ninomiya
Hironori Ninomiya
YIYuichi Ishikawa
Yuichi Ishikawa
A subset of lung cancers harbors a small inversion within chromosome 2p, giving rise to a transforming fusion gene, EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene), which encodes an activated tyrosine kinase. We have earlier examined the presence of EML4-ALK by multiplex reverse transcription-polymerase chain reaction in 363 specimens of lung cancer, identifying 11 adenocarcinoma cases featuring the fusion gene. In this study, we clinicopathologically examined the characteristics of the EML4-ALK-positive cases, including the mutation status of EGFR, KRAS, and TP53, and whether they were of thyroid transcription factor-1 (TTF-1) cell lineage or not. Of 11 patients, 4 (36%) with EML4-ALK-positive lung adenocarcinomas who were below 50 years of age were affected by these diseases, as compared with 12 of 242 patients (5.0%) with EML4-ALK-negative lung adenocarcinomas (P=0.00038). EML4-ALK-positive lung adenocarcinomas were characterized by less-differentiated grade (P=0.0082) and acinar-predominant structure (P<0.0001) in histology. Furthermore, the presence of EML4-ALK appears to be mutually exclusive for EGFR and KRAS mutations (P=0.00018), whereas coexisting with TP53 mutations at a low frequency (1/11=9.1%), and correlating with non- or light smoking (P=0.040), in line with the TTF-1 immunoreactivity. Thus, EML4-ALK-positive tumors may form a distinct entity among lung adenocarcinomas, characterized by young onset, acinar histology, no or rare mutations in EGFR, KRAS, and TP53, and a TTF-1 cell lineage, all in agreement with the prevalence in non- or light smokers.

1 October 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TYTatsuya Yoshida
Tatsuya Yoshida
YOYuko Oya
Yuko Oya
KTKosuke Tanaka
Kosuke Tanaka
JSJunichi Shimizu
Junichi Shimizu
YHYoshitsugu Horio
Yoshitsugu Horio
YYYasushi Yatabe
Yasushi Yatabe
Purpose: Anaplastic lymphoma kinase (ALK) rearrangement–positive non–small-cell lung cancers can be effectively treated with an ALK tyrosine kinase inhibitor (TKI) such as crizotinib, but the response magnitude and duration are heterogeneous. Several ALK variants have been identified, but few studies have focused on the effects of different ALK variants on the efficacy of crizotinib. Patients and Methods: Among 55 patients treated with crizotinib as the initial ALK-TKI between January 2007 and December 2014, we identified 35 patients with tumor specimens that could be evaluated for ALK variants by reverse transcription polymerase chain reaction. We retrospectively evaluated the efficacy of crizotinib on the basis of the objective response rate and progression-free survival (PFS) according to the ALK variants. Results: The most frequent ALK variant was variant 1 in 19 patients (54%), followed by variant 2 in five patients (14%), variant 3a/3b in four patients (12%), and other variants in seven patients (20%). Objective response rate was 69% in all patients, whereas it was 74% and 63% in the variant 1 and non–variant 1 groups, respectively. The median PFS time was significantly longer in patients with variant 1 than in those with non–variant 1 (median PFS, 11.0 months [95% CI, 6.5 to 43.0 months] v 4.2 months [95% CI, 1.6 to 10.2 months], respectively; P < .05). Multivariable analysis identified two significant factors associated with PFS duration, ALK variant 1 (hazard ratio, 0.350; 95% CI, 0.128 to 0.929; P < .05) and advanced stage (hazard ratio, 4.646; 95% CI, 1.381 to 21.750; P < .05). Conclusion: Our results indicate the better efficacy of crizotinib in patients with ALK variant 1 versus non–variant 1. The ALK variant status might affect the efficacy of ALK-TKIs.

30 October 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
YKY. Kobayashi
Y. Kobayashi
TMTetsuya Mitsudomi
Tetsuya Mitsudomi
YSYukinori Sakao
Yukinori Sakao
YYY. Yatabe
Y. Yatabe
Pulmonary ground-glass nodules (GGNs) include both malignant and benign lesions. Some GGNs become larger, whereas others remain unchanged for years. We have previously reported that smoking history and large diameters are predictors for growth. However, the genetic differences among GGNs remain unclear. GGNs with ground-glass component of ≥50% on a thin-section computed tomography scan that were resected between 2012 and 2014 were evaluated for clinicopathological features and the presence of EGFR/KRAS/ALK/HER2 mutations. ‘Incidence of 2-mm growth’ and ‘Time to 2-mm growth’ were analyzed according to the mutational status. Among 104 GGNs in 96 patients, this study included 3 atypical adenomatous hyperplasia (AAH), 19 adenocarcinoma in situ (AIS), 27 minimally invasive adenocarcinoma (MIA), and 55 invasive adenocarcinoma (IA). Among the 71 lesions evaluable for growth, 30 GGNs exhibited growth and 5 lesions remained unchanged for ≥2 years before surgery was carried out. We identified mutations or rearrangements in 75% of GGNs (78/104). EGFR mutations were noted in 64% of samples, KRAS in 4%, ALK in 3%, and HER2 in 4%. The remaining 26 quadruple-negative tumors were significantly associated with AAH/AIS (P < 0.01) and no-growth (P < 0.01) compared with driver mutation-positive tumors, whereas EGFR mutation-positive tumors were correlated with MIA/IA (P < 0.01) and growth (P < 0.01) compared with EGFR-negative tumors. Three fourths of resected GGNs were positive for EGFR, KRAS, ALK, or HER2 mutations. Quadruple-negative tumors were associated with a lack of GGN growth, whereas EGFR mutation-positive tumors displayed a correlation with growth.

7 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YOYuko Oya
Yuko Oya
TYTatsuya Yoshida
Tatsuya Yoshida
HKHiroaki Kuroda
Hiroaki Kuroda
MMMasashi Mikubo
Masashi Mikubo
CKChiaki Kondo
Chiaki Kondo
YYYasushi Yatabe
Yasushi Yatabe
Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

10 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SMShunsuke Mori
Shunsuke Mori
NUNoriyasu Usami
Noriyasu Usami
KFKoichi Fukumoto
Koichi Fukumoto
TMTetsuya Mizuno
Tetsuya Mizuno
HKHiroaki Kuroda
Hiroaki Kuroda
YSYukinori Sakao
Yukinori Sakao
Immunological parameters and nutritional status influence the outcome of patients with malignant tumors. A prognostic nutritional index, calculated using serum albumin levels and peripheral lymphocyte count, has been used to assess prognosis for various cancers. This study aimed to investigate whether this prognostic nutritional index affects overall survival and the incidence of postoperative complications in patients with completely resected non-small cell lung cancer. We retrospectively reviewed the medical records of 409 patients with non-small cell lung cancer who underwent complete resection between 2005 and 2007 at the Aichi Cancer Center. The 5-year survival rates of patients with high (≥50) and low (<50) prognostic nutritional indices were 84.4% and 70.7%, respectively (p = 0.0011). Univariate analysis showed that gender, histology, pathological stage, smoking history, serum carcinoembryonic antigen levels, and prognostic nutritional index were significant prognostic factors. Multivariate analysis identified pathological stage and the prognostic nutritional index as independent prognostic factors. The frequency of postoperative complications tended to be higher in patients with a low prognostic nutritional index. The prognostic nutritional index is an independent prognostic factor for survival of patients with completely resected non-small cell lung cancer.

1 January 2014 in Lung Cancer
Verified
Journal Article
Closed access
YKYoshihisa Kobayashi
Yoshihisa Kobayashi
YSYukinori Sakao
Yukinori Sakao
GDGautam A. Deshpande
Gautam A. Deshpande
TFTakayuki Fukui
Takayuki Fukui
HKHiroaki Kuroda
Hiroaki Kuroda
TMTetsuya Mitsudomi
Tetsuya Mitsudomi